Select Location
We need your delivery location to continue browsing
Prescription Required
cipla ltd
28 tablet
Ledipasvir (90mg) + Sofosbuvir (400mg)
Keep in cold place
Delivering To:
Overview
Hepcvir L (Sofosbuvir 400mg and Ledipasvir 90mg) Tablet is a combination of two antiviral medications, used in the treatment of chronic (long-lasting) hepatitis C virus (HCV) infection in adults. It is a fixed-dose combination of Ledipasvir and Sofosbuvir. Ledipasvir and Sofosbuvir are direct-acting antiviral medications. Hepcvir L Tablet is an antiviral medicine that works to lower the multiplication of viruses in the body and eliminates the virus from the body over a while.
Hepatitis C
Hepcvir L Tablet contains Ledipasvir and Sofosbuvir. Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication. Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a nucleotide prodrug, that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.
Thorough QT studies have been conducted for Sofosbuvir/Ledipasvir. The effect of Ledipasvir 120 mg twice daily (2.67 times the maximum recommended dosage) for 10 days on QTc interval was calculated in a randomized, multiple-dose, placebo- and active-controlled (moxifloxacin 400 mg), three-period, crossover thorough QT trial in 59 healthy subjects. At the dose of 120 mg twice daily (2.67 times the maximum recommended dosage), Ledipasvir does not prolong the QTc interval to any clinically relevant extent. The effect of Sofosbuvir 400 mg (maximum recommended dosage) and 1,200 mg (three times the maximum recommended dosage) on QTc interval was calculated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg), four-period, crossover thorough QT trial in 59 healthy subjects. At a dose three times the maximum recommended dose, Sofosbuvir does not prolong QTc to any clinically relevant extent.
Most side effects of Hepcvir L Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.
Headache
Nausea
Insomnia
Fever
Chills
Muscle pain
Cramps
Tiredness
Diarrhea
Fainting
Loss of appetite
Skin rash
Itching
Irritability
Take the dose exactly as your healthcare provider directs. Do not crush, break, or chew the tablet.
In case of an overdose, make sure to seek immediate medical support.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Hepcvir L Tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Sofosbuvir 400mg and Ledipasvir 90mg tablets without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
Take the next scheduled dose if you miss a dose (if it is already the time for your next dose). Do not double the dose strength in order to catch up.
Hepcvir L (Sofosbuvir 400mg and Ledipasvir 90mg) Tablet is a combination of two antiviral medications, used in the treatment of chronic (long-lasting) hepatitis C virus (HCV) infection in adults.
Take the dose exactly as your healthcare provider directs. Do not crush, break, or chew the tablet.
Store at room temperature (10-30°C). Keep it away from direct light, moisture, and heat.
No, Hepcvir L is not a habit-forming medicine.
If you feel unwell after the consumption of the Hepcvir L tablet, avoid driving and operating heavy machines.